The evidence
Ipamorelin research: the skeletal data, the mechanism, and the human trial
Mechanism first, then the bone studies that lead this digest, then pharmacokinetics, the lone human trial, and the comparison questions — each finding tied to its source.
Before the details
Here is the Ipamorelin research in plain terms. It is a lab-made peptide that gets the pituitary gland to release a pulse of growth hormone by acting on the ghrelin receptor — the same receptor the hunger hormone uses. Its special quality is selectivity: it raises growth hormone without raising stress hormones [1]. The most-studied outcome is bone. In rats, it made long bones grow faster in proportion to the dose, and it did so without changing blood IGF-1, the liver-made growth messenger [4]. In humans, almost nothing has been tested: one trial for post-surgery bowel recovery did not work [3], and a small study measured how fast it clears the body [2]. Below, each finding is broken out with the species, the dose, and the route, so you can see exactly what was measured and where the evidence runs out.
Mechanism: a selective doorway into growth hormone
Ipamorelin is a synthetic pentapeptide (a five-amino-acid chain, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) on pituitary somatotrophs — the growth-hormone-making cells. Activation triggers a calcium signal inside those cells and a discrete pulse of growth hormone [1]. The defining result, established in 1998, is selectivity: potent growth-hormone release with no meaningful rise in ACTH or cortisol even at more than 200 times the growth-hormone threshold, in rat cells, anaesthetised rats, and conscious swine (swine ED50 2.3 nmol/kg) [1]. Because it works through the ghrelin receptor rather than the GHRH receptor, its mechanism is distinct from and complementary to GHRH analogs — the pharmacological basis for combining it with one.
The skeletal record: dose-dependent bone growth
The bone data lead this digest because they are the most quantitative. Subcutaneous ipamorelin at 18, 90, and 450 micrograms a day (split across three daily doses for 15 days) raised the longitudinal bone-growth rate of adult female Sprague-Dawley rats from 42 micrometers a day on vehicle to 44, 50, and 52 micrometers a day — a clean dose-response — with no change in total IGF-1, IGF-binding proteins, or bone-turnover markers [4]. The unchanged IGF-1 is the interesting part: it argues the skeletal effect is driven partly by the local growth-hormone pulse rather than by systemic growth factor [4].
Delivered continuously by osmotic minipump at 0.5 mg/kg per day for 12 weeks, ipamorelin increased total tibial and vertebral bone mineral content by DXA, while cortical volumetric bone mineral density stayed unchanged — bigger bones, not denser ones [8]. And in a steroid-loss model, 100 micrograms/kg three times daily for three months alongside methylprednisolone raised the periosteal bone-formation rate roughly four-fold over the steroid alone and increased maximum tetanic muscle tension [7]. A related study showed the growth-hormone response to ipamorelin survived glucocorticoid suppression, with IGF-1 raised and body weight recovered in combination [13].
Pharmacokinetics: how long it lasts
The cleanest human data are pharmacokinetic. Population PK/PD modeling in healthy male volunteers (eight per dose level; five 15-minute IV infusions of 4.21 to 140.45 nmol/kg) showed dose-proportional kinetics, a terminal half-life of about two hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg; the growth-hormone response peaked near 40 minutes as a single discrete pulse [2]. In male rats, ipamorelin showed roughly five-fold lower plasma clearance than GHRP-6, with 60 to 80 percent of the dose recovered intact in bile and urine, and an intranasal bioavailability of about 20 percent [5]. A peptidomimetic series built on ipamorelin's scaffold later reached roughly 10 percent oral bioavailability in dogs while keeping potency — evidence the pharmacophore could be engineered toward an oral GH secretagogue, though ipamorelin itself is not orally bioavailable [14].
The human trial — and the most recent study
<a id="fda-status"></a>The only published Phase 2 RCT (NCT00672074) gave 0.03 mg/kg IV twice daily for up to seven days to 114 adults after bowel resection. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (p=0.15), with treatment-emergent adverse events in 87.5 percent of the ipamorelin arm versus 94.8 percent of placebo — no ipamorelin-specific safety signal in that short window, but no demonstrated efficacy either [3]. Is ipamorelin FDA approved? No — it has never been approved for any indication by the FDA or any other regulator [3]. The most recent in-vivo study (2024) found that intraperitoneal ipamorelin (1–3 mg/kg) reduced cisplatin-induced body-weight loss in ferrets by about 24 percent in the delayed phase, but had no anti-emetic effect [16].
Ipamorelin cjc-1295
<a id="cjc-1295"></a>Ipamorelin cjc-1295 is the most-searched pairing, so it is worth being precise. What is CJC-1295 ipamorelin? It is a research combination of two different peptides: CJC-1295, a GHRH analog that acts on the GHRH receptor, and ipamorelin, a ghrelin-receptor agonist. The rationale is that they raise growth hormone through two separate, complementary doorways [1]. <a id="does-stack-work"></a>Does CJC-1295 ipamorelin work? Evidence is limited to animal studies: a 2026 narrative review reported that CJC-1295 combined with ipamorelin improved maximum tetanic muscle tension in a glucocorticoid-induced muscle-loss model in mice, while cautioning that the human evidence base is not established [15]. The combination has never been tested in a controlled human trial for any outcome — its support rests on the separate single-agent pharmacology, not on trials of the pairing itself [3].
Ipamorelin vs sermorelin
<a id="vs-sermorelin"></a>Ipamorelin vs sermorelin is a comparison of two mechanisms, not two versions of one thing. Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist — a growth-hormone-releasing peptide that mimics the hunger hormone to release a growth-hormone pulse [1]. Sermorelin is a GHRH analog, acting on the separate GHRH receptor. Because they hit different receptors, their pharmacology differs and the two are sometimes discussed as complementary rather than interchangeable. The evidence bases differ sharply too: ipamorelin's most quantitative data are the rodent bone studies [4] [8] and its lone human trial missed [3]. This digest does not claim one is superior; it documents what each mechanism is and where ipamorelin's evidence sits.
Ipamorelin vs tesamorelin
<a id="vs-tesamorelin"></a>Ipamorelin vs tesamorelin contrasts an unapproved ghrelin-receptor agonist with a GHRH-receptor analog. Ipamorelin releases growth hormone through the ghrelin receptor [1] and has no approved indication anywhere [3]. Tesamorelin is a GHRH analog studied and approved in its own regulatory context for a specific population — a different mechanism, a different evidence base, and a different regulatory status. The two are not equivalent and were developed for different purposes. Within this site's scope, the relevant point is that ipamorelin's defining trait is selectivity at the ghrelin receptor [1], and its skeletal data — the lens this digest leads with — are preclinical [4].